KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cash from Operations: 2017-2025

Historic Cash from Operations for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $118.5 million.

  • Amneal Pharmaceuticals' Cash from Operations fell 16.45% to $118.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $327.8 million, marking a year-over-year increase of 4.77%. This contributed to the annual value of $295.1 million for FY2024, which is 14.61% down from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Cash from Operations of $118.5 million as of Q3 2025, which was up 41.32% from $83.8 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Cash from Operations ranged from a high of $148.1 million in Q1 2021 and a low of -$125.5 million during Q2 2022.
  • Over the past 3 years, Amneal Pharmaceuticals' median Cash from Operations value was $83.8 million (recorded in 2025), while the average stood at $77.3 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first slumped by 141.70% in 2022, then surged by 683.13% in 2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Cash from Operations (Quarterly) stood at $63.3 million in 2021, then tumbled by 136.82% to -$23.3 million in 2022, then skyrocketed by 683.13% to $135.8 million in 2023, then fell by 13.06% to $118.1 million in 2024, then fell by 16.45% to $118.5 million in 2025.
  • Its Cash from Operations was $118.5 million in Q3 2025, compared to $83.8 million in Q2 2025 and $7.4 million in Q1 2025.